Cullinan Therapeutics, Inc. (CGEM)
(Delayed Data from NSDQ)
$16.30 USD
-0.47 (-2.80%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $16.24 -0.06 (-0.37%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CGEM 16.30 -0.47(-2.80%)
Will CGEM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CGEM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGEM
Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
CGEM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?
Other News for CGEM
Morgan Stanley Remains a Buy on Cullinan Management (CGEM)
Wedbush Remains a Buy on Cullinan Management (CGEM)
Cullinan Management: A Buy Rating on Strong Financials and Promising Clinical Trials
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
CGEM Stock Earnings: Cullinan Therapeutics Misses EPS for Q2 2024